retatrutide nonalcoholic fatty liver disease nash trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic disease: a randomized phase 2a retatrutide nonalcoholic fatty liver disease

1498506 Unger RH, Orci L (1976) Physiology and pathophysiology of glucagon

What the new mechanism is: GLP-1 : appetite regulation, improved glucose control GIP : incretin effects that may augment metabolic benefits Glucagon receptor activity : potentially influences energy expenditure and fat metabolism (while requiring careful balancing of tolerability and metabolic effects) What results look like (so far): Phase 2 (48 weeks) published in NEJM showed substantial mean weight reductions (with higher doses showing very large effects)

It is worth noting that the amino acid sequence of romiplostim is not similar to the endogenous thrombopoietin

Published clinical studies have evaluated investigational retatrutide under controlled research conditions, but those findings should not be interpreted as evidence that this research product is approved for patient care

Think of GHK-Cu as helping your skin clean up and rebuild at the same time